Pakistan Enlistment vs Registration: The Two Statutory Routes

1. Key takeaways

Device market access in Pakistan runs through two statutory channels, set out expressly in Rule 13 of the Medical Devices Rules, 2017: Class A follows “enlistment”, while Class B, C and D follow “registration”. The two channels use different forms — on the import route, Class A uses Form-6A and Classes B/C/D use Form-7A — and they differ in depth of review, because registration requires more complete technical, clinical and quality system evidence. Getting the channel right is the first gate in any Pakistan project: it fixes the form, the fee band, the evidence plan and the review expectations in one stroke, and every downstream task inherits from that single determination. A team that starts drafting before answering the channel question usually has to redo the work, because the form choice cannot be changed retroactively without restarting the filing.

• The channel is fixed by the class of the device, not chosen by the applicant.
• Forms come in local/import pairs: Form-6/6A for Class A and Form-7/7A for B/C/D.
• Rule 14 governs who may apply, what must accompany the form, and when an application may be returned.
• Enlistment is a full statutory procedure in its own right, not an exemption from procedure.

2. Legal basis

The table below collects the Rule 13 and Rule 14 provisions that define the two routes, together with the amendment order that revised the forms. Read together, these provisions show that the route determination and the application mechanics sit in the same part of the rules, which is why a classification error and a form error so often travel together.

3. Expert insights

Insight 1: “Enlistment” does not mean “exempt from registration”; it is another statutory procedure. Chinese-language materials often describe Class A enlistment as “no registration required”, which misreads “a different form” as “no procedure”. Class A still requires a qualified applicant to submit Form-6A, pay the fee and provide the specified materials; only the depth of the review is shallower than the registration of B/C/D. Companies that act on the loose translation may skip evidence preparation, miss the validation requirements that apply to every class, and then face avoidable deficiency letters. The safe operating rule is simple: Class A is a lighter file, never an empty one. The evidence is still real evidence, produced under a quality system, and the reviewer still has authority to return the application if the fee or the materials fall short under Rule 14(4).

Insight 2: The forms of the two channels come in local/import pairs. Form-6 (local manufacture) corresponds to Form-6A (import), and Form-7 (local manufacture) corresponds to Form-7A (import). Choosing the wrong form amounts to filing an invalid application. The pairing also means that a company with both local production and import activities cannot merge the two filings into one dossier: each activity is applied for on its own form, with its own fee and its own certificate, and mixing them invites a return under Rule 14(4).

Insight 3: The validation principles in Rule 14(5) are the technical clause most easily missed. The provision requires that the production methods and testing methods of the device comply with validation principles. This means the methodological data submitted must itself have been validated, not merely that “a method exists”. In practice, this clause pulls quality system content into an otherwise form-driven filing: process validation and test method validation records should be identifiable in the dossier, because a reviewer checking Rule 14(5) compliance will look for evidence of validation, not assertions of it. Teams translating dossiers from markets where testing methods are described without validation status should rebuild those sections rather than reuse them, since the gap is exactly the kind of detail this clause targets.

4. Practical recommendations

• The first question GRZAN asks when determining the channel is: which Class is the device? The second question is: is the applicant a local manufacturer or an importer? Once both are answered, the form is fixed.
• Table 6/6A (Class A) and 7/7A (B/C/D) are maintained as two separate checklists, each used independently, with no cross-application permitted.
• For clients with both local production and import business in Pakistan, two separate dossiers are built.
• Fees are verified against the current Schedule C for each filing, so that the fee line matches the form actually submitted.
• Validation records for production and testing methods are confirmed present before filing, in anticipation of Rule 14(5) review.
• Return risks under Rule 14(4) are screened before submission: the fee receipt and every material listed on the form are checked against the checklist.

5. Verification checklist

• □ Confirmed Class A → enlistment (Form-6A); B/C/D → registration (Form-7A)
• □ Confirmed whether the applicant is a local manufacturer or an importer, and selected the corresponding form
• □ Checked the current fees against rule 63
• □ Prepared the materials, documents and samples listed in the form
• □ Checked whether production and testing methods satisfy the validation principles

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com